Clinical Trial Search

Primary: Objective Response Rates (Partial and Complete Responses) — 0 participants

Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (Non-inferiority Analysis). — 0.080; 0.019 Liters — p=0.004

Primary: Change in Hemoglobin A1c — 2.67; 1.05 percentage change from baseline

Primary: Number of Participants for Which Angiograghy is Used to Visualize Nasoseptal Mucosa Better Than What is Done Standard of Care in This Surgery. — 5 Participants

Primary: Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc — 3441; 2954; 2181; 2947 nanogram*hour per milliliter (ng*hr/mL)…

Primary: 6-month Progression-free Survival (PFS) Rate — 0.792 proportion of patients progression-free

Primary: Laryngoscopic Score — 1; 0; 11; 0 Participants — p=0.05

Primary: Number of Participants With Symptomatic Intracerebral Hemorrhage Within 36 Hours of Treatment — 0 participants

Primary: Total Number of Detectable Plaque Bacteria Sampled 3 Days Post Implant Surgery — 7.63; 7.43 log(10) colony forming equivalents (CFE) — p=0.2965

Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…

Primary: Survival — 80 percentage of survival at 30 days

Primary: Overall Survival — 5.8; 5.1 years — p=0.15

Primary: The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) — 6 Participants

Primary: Count of Participants Who Self-reported "Adequate Relief" — 12; 15 Participants — p=0.59

Primary: Response (Complete and Partial Response) in Patients With Myeloid Disorders — 0; 1; 2; 5 Participants